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I. General Information 
 
Unless otherwise noted, reagents were used as received from commercial suppliers. All 
reactions were performed under an atmosphere of dry nitrogen. Anhydrous chloroform, 1,2-
dimethoxyethane (DME), and cyclopentyl methyl ether (CPME) were purchased from Sigma-
Aldrich and stored under nitrogen. Other solvents were purified by passage through activated 
aluminum oxide using a solvent-purification system. 
NMR spectra were recorded on a Bruker spectrometer with a Prodigy broadband 
cryoprobe (400 MHz for 1H and 101 MHz for 13C); chemical shifts (δ) are reported in ppm 
downfield from tertramethylsilane, using the solvent resonance as the internal standard. 
Optical rotation data were obtained with a Jasco P-2000 polarimeter at 589 nm, using a 100 mm 
path-length cell in the solvent and at the concentration indicated. Mass spectra were obtained 
on an Agilent 7890A GC-MS system with an Agilent 5975C detector or on an Agilent 1290 
UHPLC-LCMS system with an Agilent 6140 detector. HPLC analyses were carried out on an 
Agilent 1100 series system with Daicel CHIRALPAK® or Daicel CHIRALCEL® columns 
(internal diameter 4.6 mm, column length 250 mm, particle size 5 µm). IR spectra were 
recorded on a Thermo Scientific Nicolet iS5 (iD5 ATR) spectrometer by attenuated total 
refection (ATR). 
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II. Preparation of Electrophiles 
 
General Procedure 1 (GP-1): Preparation of racemic secondary benzylic chlorides. 
 
Preparation of the benzylic alcohol. A solution of ArMgBr (1.0 M in THF; 33 mmol, 1.1 
equiv;) was added dropwise over 5 min to an oven-dried flask charged with a solution of the 
aldehyde (30 mmol, 1.0 equiv) in anhydrous THF (40 mL) at 0 °C. Next, the reaction mixture 
was allowed to slowly warm to room temperature, and it was stirred overnight. Then, the 
reaction mixture was cooled to 0 °C, and the reaction was quenched by the slow addition of a 
saturated aqueous solution of NH4Cl (40 mL). The layers were separated, and the aqueous 
layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over 
anhydrous MgSO4, filtered, and concentrated. The residue was purified by column 
chromatography on silica gel to provide the desired product. 
Preparation of the benzylic chloride. Thionyl chloride (2.3 mL, 31.5 mmol, 1.05 equiv) was 
added dropwise over 2 min to an oven-dried flask charged with a solution of the benzylic 
alcohol (30 mmol, 1.0 equiv) in CHCl3 (20 mL) at 0 °C (CAUTION: gas formation). Then, the 
reaction mixture was allowed to slowly warm to room temperature. The progress of the 
reaction was monitored by GC analysis. After completion, the reaction mixture was 
concentrated under reduced pressure, and the residue was purified by column 
chromatography on silica gel to provide the desired product. 
 
The yields have not been optimized. 
 
 
(6-(Benzyloxy)-1-chlorohexyl)benzene. The title compound was synthesized according to 
GP-1 from 6-(benzyloxy)hexanal1 and phenylmagnesium bromide, and it was purified by 
column chromatography on silica gel (5% Et2O in hexanes). 62% yield over 2 steps; colorless 
oil. 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.35 (m, 8H), 7.35 – 7.29 (m, 2H), 4.88 (dd, J = 8.1, 6.4 Hz, 
1H), 4.53 (s, 2H), 3.49 (t, J = 6.5 Hz, 2H), 2.23 – 2.13 (m, 1H), 2.11 – 2.06 (m, 1H), 1.67 – 1.60 (m, 
2H), 1.59 – 1.51 (m, 1H), 1.48 – 1.42 (m, 2H), 1.39 – 1.33 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 141.9, 138.6, 128.6, 128.4, 128.2, 127.6, 127.5, 126.9, 72.9, 70.2, 
63.8, 39.9, 29.6, 26.9, 25.7. 
FT-IR (film) 3030, 2936, 1454, 1362, 1102, 696 cm-1. 
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6-Chloro-6-phenylhexyl benzoate. The title compound was synthesized according to GP-1 
from 6-oxohexyl benzoate2 and phenylmagnesium bromide, and it was purified by column 
chromatography on silica gel (10% Et2O in hexanes). 74% yield over 2 steps; pale-yellow oil. 
1H NMR (400 MHz, CDCl3) δ 8.11 – 8.01 (m, 2H), 7.63 – 7.55 (m, 1H), 7.51 – 7.44 (m, 2H), 
7.44 – 7.35 (m, 4H), 7.35 – 7.29 (m, 1H), 4.89 (dd, J = 8.2, 6.4 Hz, 1H), 4.34 (t, J = 6.6 Hz, 2H), 2.25 
– 2.14 (m, 1H), 2.12 – 2.04 (m, 1H), 1.84 – 1.75 (m, 2H), 1.68 – 1.58 (m, 1H), 1.56 – 1.48 (m, 2H), 
1.47 – 1.39 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 166.6, 141.8, 132.9, 130.4, 129.5, 128.6, 128.4, 128.3, 126.9, 64.8, 
63.7, 39.9, 28.6, 26.8, 25.6. 
FT-IR (film) 3031, 2941, 1718, 1452, 1274, 1117, 1070, 711 cm-1. 
 
 
 
(1,6-Dichlorohexyl)benzene. The title compound was synthesized according to GP-1 from 
6-chlorohexanal3 and phenylmagnesium bromide, and it was purified by column 
chromatography on silica gel (hexanes). 54% yield over 2 steps; colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.37 (m, 4H), 7.36 – 7.32 (m, 1H), 4.88 (dd, J = 8.2, 6.3 Hz, 
1H), 3.55 (t, J = 6.6 Hz, 2H), 2.23 – 2.13 (m, 1H), 2.13 – 2.04 (m, 1H), 1.82 – 1.76 (m, 2H), 1.58 – 
1.48 (m, 3H), 1.43 – 1.34 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 141.8, 128.7, 128.3, 126.9, 63.6, 44.9, 39.8, 32.4, 26.4, 26.3. 
FT-IR (film) 2939, 1493, 1454, 1310, 698 cm-1. 
 
  
                                                
[2] J. E. Wilson, A. D. Casarez, D. W. C. MacMillan, J. Am. Chem. Soc. 2009, 131, 11332–11334. 
[3] R. J. Fox, G. Lalic, R. G. Bergman, J. Am. Chem. Soc. 2007, 129, 14144–14145. 
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III. Catalytic Enantioconvergent Borylations 
 
 
General Procedure 2 (GP-2): Catalytic enantioconvergent borylation. 
Preparation of the catalyst. NiCl2·glyme (15 mg, 0.070 mmol, 10 mol%) and L1 (33 mg, 
0.084 mmol, 12 mol%) were added to an oven-dried 20 mL vial that contained a magnetic stir 
bar. The vial was capped with a PTFE-lined septum cap, and then it was evacuated and 
backfilled with nitrogen (3 cycles; caution: light powder, so evacuate and backfill slowly). 
DME (3.5 mL) was added via syringe, the vial was detached from the Schlenk line, and a 
nitrogen-filled balloon was attached to the vial. The resulting suspension was stirred at room 
temperature for 1 h. 
Preparation of a solution of the nucleophile. An oven-dried 8 mL vial that contained a 
magnetic stir bar was charged with t-BuOK (110 mg, 0.98 mmol, 1.4 equiv). The vial was 
capped with a PTFE-lined septum cap, and then it was evacuated and backfilled with nitrogen 
(3 cycles; caution: light powder, so evacuate and backfill slowly). Next, CPME (2.1 mL) was 
added via syringe, followed by 2-phenylethanol (126 µL, 1.05 mmol, 1.5 equiv). The resulting 
suspension was stirred at room temperature for 3 min. Under the protection of a flow of 
nitrogen, B2pin2 (249 mg, 0.98 mmol, 1.4 equiv) was added quickly to the suspension. The vial 
was then evacuated quickly (bubbles form) and backfilled with nitrogen (3 cycles). Next, the 
vial was detached from the Schlenk line, and a nitrogen-filled balloon was attached to the vial. 
The resulting suspension was stirred at room temperature for 40 min, leading to a colorless 
viscous solution. 
Enantioconvergent borylation. The benzylic chloride (0.70 mmol, 1.0 equiv) was added via 
syringe to the suspension of the catalyst. The resulting mixture was stirred for 5 min, and then 
the solution of the nucleophile was added via syringe over ~1 min. Next, the balloon was 
removed, and all of the puncture holes in the septum cap were covered with stopcock grease. 
The resulting mixture was stirred at room temperature for 3 h. 
Workup. The reaction mixture was filtered through a short pad of silica gel, eluting with 
Et2O (10 mL). The filtrate was concentrated, and the residue was purified by column 
chromatography on silica gel (if the products are exposed to silica gel for an extended period 
time or are left unpurified for over 12 h, a lower yield may be observed). 
 
General Procedure 3 (GP-3): Determination of enantioselectivity. The purified product 
(~15 mg) was stereospecifically oxidized with NaBO3·4H2O (~100 mg) in THF/H2O (1:1; 2.0 mL) 
at room temperature for 4 h. The mixture was extracted with Et2O (3.0 mL), the organic phase 
was dried over anhydrous Na2SO4, and the volatiles were removed under reduced pressure. 
The ee of the benzylic alcohol was determined via HPLC analysis, without further purification. 
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4,4,5,5-Tetramethyl-2-(1-phenylpropyl)-1,3,2-dioxaborolane (Table 2, Entry 1). The title 
compound was synthesized according to GP-2 from (1-chloropropyl)benzene and B2pin2, and 
it was purified by column chromatography on silica gel (5% Et2O in hexanes). Colorless oil. 
(R,S)-L1: 141 mg, 82% yield, 86% ee; (S,R)-L1: 137 mg, 80% yield, 86% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL OD-H 
column (3% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 10.5 min (minor), 12.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.21 – 7.12 (m, 4H), 7.08 – 7.02 (m, 1H), 2.14 (t, J = 7.9 Hz, 1H), 
1.87 – 1.73 (m, 1H), 1.66 – 1.53 (m, 1H), 1.14 (s, 6H), 1.12 (s, 6H), 0.83 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 143.4, 128.4, 128.2, 125.1, 83.2, 25.8, 24.7, 24.6, 13.9. 
FT-IR (film): 2977, 1451, 1371, 1324, 1144, 968, 850, 701 cm–1. 
LC-MS (ESI) m/z (M+H)+ calcd for C15H24BO2: 247.2, found: 247.2. 
[α]23D = +18 (c = 1.0, CHCl3); 86% ee, from (R,S)-L1. 
 
 
 
4,4,5,5-Tetramethyl-2-(1-phenylethyl)-1,3,2-dioxaborolane (Table 2, Entry 2). The title 
compound was synthesized according to GP-2 from (1-chloroethyl)benzene and B2pin2, and it 
was purified by column chromatography on silica gel (5% Et2O in hexanes). Colorless oil. 
(R,S)-L1: 105 mg, 65% yield, 82% ee; (S,R)-L1: 101 mg, 62% yield, 81% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL OD-H 
column (3% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 11.0 min (minor), 13.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.31 – 7.23 (m, 4H), 7.20 – 7.12 (m, 1H), 2.46 (q, J = 7.5 Hz, 1H), 
1.36 (d, J = 7.5 Hz, 3H), 1.24 (s, 6H), 1.23 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 144.9, 128.3, 127.8, 125.1, 83.3, 24.7, 24.6, 17.1. 
FT-IR (film): 2978, 1459, 1379, 1322, 1144, 844, 701 cm–1. 
LC-MS (ESI) m/z (M+H)+ calcd for C14H22BO2: 233.2, found: 233.2. 
[α]23D = +8.0 (c = 1.0, CHCl3); 82% ee, from (R,S)-L1. 
 
 
 
4,4,5,5-Tetramethyl-2-(1-phenylpentyl)-1,3,2-dioxaborolane (Table 2, Entry 3). The title 
compound was synthesized according to GP-2 from (1-chloropentyl)benzene and B2pin2, and it 
was purified by column chromatography on silica gel (5% Et2O in hexanes). Colorless oil. 
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(R,S)-L1: 153 mg, 80% yield, 88% ee; (S,R)-L1: 151 mg, 79% yield, 87% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL OD-H 
column (3% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 9.7 min (minor), 10.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.19 – 7.11 (m, 4H), 7.08 – 7.01 (m, 1H), 2.21 (t, J = 7.9 Hz, 1H), 
1.85 – 1.70 (m, 1H), 1.64 – 1.52 (m, 1H), 1.26 – 1.15 (m, 4H), 1.13 (s, 6H), 1.11 (s, 6H), 0.78 (t, J = 
7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 143.5, 128.4, 128.2, 125.1, 83.2, 32.3, 31.6, 24.65, 24.60, 22.7, 14.1. 
FT-IR (film): 2979, 1451, 1371, 1323, 1144, 967, 849, 701 cm–1. 
LC-MS (ESI) m/z (M+H)+ calcd for C17H28BO2: 275.2, found: 275.2. 
[α]23D = +18 (c = 1.0, CHCl3); 88% ee, from (R,S)-L1. 
 
 
 
4,4,5,5-Tetramethyl-2-(3-methyl-1-phenylbutyl)-1,3,2-dioxaborolane (Table 2, Entry 4). 
The title compound was synthesized according to GP-2 from (1-chloro-3-methylbutyl)benzene 
and B2pin2, and it was purified by column chromatography on silica gel (5% Et2O in hexanes). 
Colorless oil. 
(R,S)-L1: 154 mg, 80% yield, 88% ee; (S,R)-L1: 164 mg, 85% yield, 87% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL OD-H 
column (3% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 8.8 min (major), 9.9 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.19 – 7.12 (m, 4H), 7.08 – 7.01 (m, 1H), 2.34 (t, J = 8.1 Hz, 1H), 
1.65 – 1.50 (m, 2H), 1.45 – 1.35 (m, 1H), 1.12 (s, 6H), 1.10 (s, 6H), 0.81 (d, J = 6.5 Hz, 3H), 0.79 (d, 
J = 6.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 143.5, 128.3, 128.2, 125.0, 83.2, 41.5, 26.9, 24.6, 23.0, 22.2. 
FT-IR (film): 2979, 1452, 1370, 1323, 1144, 968, 851, 701 cm–1. 
LC-MS (ESI) m/z (M+H)+ calcd for C17H28BO2: 275.2, found: 275.2. 
[α]23D = +26 (c = 1.0, CHCl3); 88% ee, from (R,S)-L1. 
 
 
 
2-(Cyclohexyl(phenyl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, Entry 5). 
The title compound was synthesized according to GP-2 from 
(chloro(cyclohexyl)methyl)benzene and B2pin2, and it was purified by column chromatography 
on silica gel (5% Et2O in hexanes). Colorless oil. 
(R,S)-L1: 136 mg, 65% yield, 78% ee; (S,R)-L1: 120 mg, 57% yield, 77% ee. 
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HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL OD-H 
column (3% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 9.9 min (major), 11.6 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.28 – 7.18 (m, 4H), 7.18 – 7.10 (m, 1H), 2.06 (d, J = 10.4 Hz, 
1H), 1.92 – 1.77 (m, 2H), 1.77 – 1.68 (m, 1H), 1.68 – 1.57 (m, 2H), 1.52 – 1.43 (m, 1H), 1.40 – 1.30 
(m, 1H), 1.21 (s, 6H), 1.20 (s, 6H), 1.17 – 1.01 (m, 3H), 0.82 – 0.65 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 141.8, 129.2, 128.0, 125.1, 83.2, 40.3, 33.8, 32.5, 26.6, 26.5, 26.3, 
24.7, 24.6. 
FT-IR (film): 2978, 1449, 1356, 1319, 1144, 973, 850, 702 cm–1. 
GC-MS (EI) m/z (M)+ calcd for C19H29BO2: 300.2, found: 300.1. 
[α]23D = +9.9 (c = 1.0, CHCl3); 78% ee, from (R,S)-L1. 
 
 
 
2-(1,2-Diphenylethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, Entry 6). The title 
compound was synthesized according to GP-2 from (1-chloroethane-1,2-diyl)dibenzene and 
B2pin2, and it was purified by column chromatography on silica gel (5% Et2O in hexanes). 
Colorless oil. 
(R,S)-L1: 164 mg, 76% yield, 82% ee; (S,R)-L1: 176 mg, 82% yield, 84% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL OD-H 
column (5% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 13.3 min (minor), 16.8 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.18 – 7.10 (m, 8H), 7.08 – 7.02 (m, 2H), 3.07 (dd, J = 13.5, 9.8 
Hz, 1H), 2.89 (dd, J = 13.5, 6.9 Hz, 1H), 2.61 (dd, J = 9.8, 6.9 Hz, 1H), 1.03 (s, 6H), 1.02 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 142.6, 141.8, 128.9, 128.4, 128.3, 128.1, 125.8, 125.4, 83.4, 38.9, 
24.6, 24.5. 
FT-IR (film): 2978, 1600, 1494, 1370, 1328, 1142, 968, 854, 699 cm–1. 
LC-MS (ESI) m/z (M+H)+ calcd for C20H26BO2: 309.2, found: 309.2. 
[α]23D = +34 (c = 1.0, CHCl3); 82% ee, from (R,S)-L1. 
 
 
 
2-(6-(Benzyloxy)-1-phenylhexyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, Entry 
7). The title compound was synthesized according to GP-2 from (6-(benzyloxy)-1-
chlorohexyl)benzene and B2pin2, and it was purified by column chromatography on silica gel 
(10% Et2O in hexanes). Colorless oil. 
(R,S)-L1: 185 mg, 67% yield, 80% ee; (S,R)-L1: 176 mg, 64% yield, 79% ee. 
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HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL AD-H 
column (3% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 20.5 min (major), 21.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.34 (m, 4H), 7.33 – 7.29 (m, 1H), 7.28 – 7.21 (m, 4H), 
7.18 – 7.13 (m, 1H), 4.51 (s, 2H), 3.46 (t, J = 6.7 Hz, 2H), 2.32 (t, J = 7.9 Hz, 1H), 1.95 – 1.80 (m, 
1H), 1.73 – 1.65 (m, 1H), 1.65 – 1.59 (m, 2H), 1.43 – 1.36 (m, 2H), 1.35 – 1.29 (m, 2H), 1.23 (s, 6H), 
1.21 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 143.4, 138.7, 128.4, 128.3, 128.2, 127.6, 127.5, 125.1, 83.2, 72.9, 
70.5, 32.5, 29.7, 29.1, 26.2, 24.7, 24.6. 
FT-IR (film): 2977, 2932, 1453, 1370, 1323, 1143, 1111, 967, 850, 699 cm–1. 
LC-MS (ESI) m/z (M+Na)+ calcd for C25H35BO3Na: 417.3, found: 417.3. 
[α]23D = +9.0 (c = 1.0, CHCl3); 80% ee, from (R,S)-L1. 
 
 
 
6-Phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexyl benzoate (Table 2, Entry 8). 
The title compound was synthesized according to GP-2 from 6-chloro-6-phenylhexyl benzoate 
and B2pin2, and it was purified by column chromatography on silica gel (10% Et2O in hexanes). 
Colorless oil. 
(R,S)-L1: 209 mg, 73% yield, 84% ee; (S,R)-L1: 216 mg, 76% yield, 82% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL AD-H 
column (10% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 12.5 min (major), 13.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.13 – 8.03 (m, 2H), 7.63 – 7.55 (m, 1H), 7.50 – 7.43 (m, 2H), 
7.29 – 7.21 (m, 4H), 7.19 – 7.11 (m, 1H), 4.31 (t, J = 6.6 Hz, 2H), 2.33 (t, J = 7.9 Hz, 1H), 1.95 – 1.85 
(m, 1H), 1.81 – 1.66 (m, 3H), 1.55 – 1.43 (m, 2H), 1.41 – 1.33 (m, 2H), 1.23 (s, 6H), 1.21 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 166.7, 143.2, 132.8, 130.5, 129.5, 128.4, 128.3, 128.2, 125.2, 83.3, 
65.1, 32.5, 28.9, 28.6, 26.1, 24.6, 24.5. 
FT-IR (film): 2977, 2932, 1720, 1451, 1371, 1323, 1274, 1143, 1115, 967, 850, 712 cm–1. 
LC-MS (ESI) m/z (M+Na)+ calcd for C25H33BO4Na: 431.2, found: 431.2. 
[α]23D = +12 (c = 1.0, CHCl3); 84% ee, from (R,S)-L1. 
 
 
 
2-(6-Chloro-1-phenylhexyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, Entry 9). The 
title compound was synthesized according to GP-2 from (1,6-dichlorohexyl)benzene and 
B2pin2, and it was purified by column chromatography on silica gel (5% Et2O in hexanes). 
Colorless oil. 
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(R,S)-L1: 189 mg, 84% yield, 86% ee; (S,R)-L1: 182 mg, 80% yield, 87% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALPAK IC 
column (3% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 10.6 min (major), 11.2 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.30 – 7.26 (m, 2H), 7.25 – 7.20 (m, 2H), 7.19 – 7.13 (m, 1H), 
3.52 (t, J = 6.8 Hz, 2H), 2.32 (t, J = 7.9 Hz, 1H), 1.93 – 1.83 (m, 1H), 1.81 – 1.73 (m, 2H), 1.73 – 1.63 
(m, 1H), 1.53 – 1.41 (m, 2H), 1.35 – 1.28 (m, 2H), 1.23 (s, 6H), 1.21 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 143.2, 128.3, 128.2, 125.2, 83.3, 45.1, 32.5, 32.4, 28.4, 26.8, 24.7, 
24.6. 
FT-IR (film): 2978, 1452, 1371, 1323, 1143, 967, 850, 701 cm–1. 
LC-MS (ESI) m/z (M+H)+ calcd for C18H29BClO2: 323.2, found: 323.2. 
[α]23D = +13 (c = 1.0, CHCl3); 86% ee, from (R,S)-L1. 
 
 
 
4,4,5,5-Tetramethyl-2-(1-(p-tolyl)propyl)-1,3,2-dioxaborolane (Table 2, Entry 10). The title 
compound was synthesized according to GP-2 from 1-(1-chloropropyl)-4-methylbenzene and 
B2pin2, and it was purified by column chromatography on silica gel (5% Et2O in hexanes). 
Colorless oil. 
(R,S)-L1: 120 mg, 66% yield, 82% ee; (S,R)-L1: 112 mg, 61% yield, 82% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL AD-H 
column (5% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 8.4 min (minor), 9.4 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.18 – 7.03 (m, 4H), 2.33 (s, 3H), 2.21 (t, J = 7.9 Hz, 1H), 1.95 – 
1.82 (m, 1H), 1.74 – 1.61 (m, 1H), 1.25 (s, 6H), 1.23 (s, 6H), 0.93 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 140.2, 134.4, 128.9, 128.3, 83.1, 26.0, 24.7, 24.6, 21.0, 13.9. 
FT-IR (film): 2978, 1462, 1360, 1322, 1144, 969, 852, 815 cm–1. 
GC-MS (EI) m/z (M)+ calcd for C16H25BO2: 260.2, found: 260.1. 
[α]23D = +17 (c = 1.0, CHCl3); 82% ee, from (R,S)-L1. 
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4,4,5,5-Tetramethyl-2-(1-(m-tolyl)propyl)-1,3,2-dioxaborolane (Table 2, Entry 11). The title 
compound was synthesized according to GP-2 from 1-(1-chloropropyl)-3-methylbenzene and 
B2pin2, and it was purified by column chromatography on silica gel (5% Et2O in hexanes). 
Colorless oil. 
(R,S)-L1: 144 mg, 79% yield, 81% ee; (S,R)-L1: 136 mg, 75% yield, 82% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL OD-H 
column (5% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 7.3 min (minor), 8.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.22 – 7.14 (m, 1H), 7.10 – 7.00 (m, 2H), 7.00 – 6.92 (m, 1H), 
2.34 (s, 3H), 2.21 (t, J = 7.9 Hz, 1H), 1.97 – 1.83 (m, 1H), 1.74 – 1.66 (m, 1H), 1.25 (s, 6H), 1.23 (s, 
6H), 0.94 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 143.2, 137.6, 129.3, 128.1, 125.9, 125.3, 83.2, 25.9, 24.7, 24.6, 21.5, 
14.0. 
FT-IR (film): 2977, 1462, 1360, 1322, 1265, 1144, 968, 860, 708 cm–1. 
GC-MS (EI) m/z (M)+ calcd for C16H25BO2: 260.2, found: 260.1. 
[α]23D = +19 (c = 1.0, CHCl3); 81% ee, from (R,S)-L1. 
 
 
 
2-(1-(3-Methoxyphenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, Entry 
12). The title compound was synthesized according to GP-2 from 1-(1-chloropropyl)-3-
methoxybenzene and B2pin2, and it was purified by column chromatography on silica gel (5% 
Et2O in hexanes). Colorless oil. 
(R,S)-L1: 137 mg, 71% yield, 82% ee; (S,R)-L1: 130 mg, 67% yield, 80% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL OD-H 
column (5% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 15.3 min (minor), 16.4 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.19 (t, J = 7.9 Hz, 1H), 6.87 – 6.79 (m, 2H), 6.71 (ddd, J = 8.2, 
2.6, 1.0 Hz, 1H), 3.81 (s, 3H), 2.22 (t, J = 7.9 Hz, 1H), 1.94 – 1.83 (m, 1H), 1.76 – 1.64 (m, 1H), 1.24 
(s, 6H), 1.22 (s, 6H), 0.93 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.5, 145.0, 129.1, 120.9, 113.9, 110.6, 83.2, 55.1, 25.8, 24.7, 24.6, 
13.9. 
FT-IR (film): 2977, 1599, 1487, 1360, 1322, 1260, 1143, 1049, 860, 706 cm–1. 
GC-MS (EI) m/z (M)+ calcd for C16H25BO3: 276.2, found: 276.1. 
[α]23D = +10 (c = 1.0, CHCl3); 82% ee, from (R,S)-L1. 
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4,4,5,5-Tetramethyl-2-(1-(o-tolyl)propyl)-1,3,2-dioxaborolane (Table 2, Entry 13). The title 
compound was synthesized according to GP-2 from 1-(1-chloropropyl)-2-methylbenzene and 
B2pin2, and it was purified by column chromatography on silica gel (5% Et2O in hexanes). 
Colorless oil. 
(R,S)-L1: 163 mg, 89% yield, 86% ee; (S,R)-L1: 160 mg, 88% yield, 86% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL AD-H 
column (3% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 8.4 min (minor), 9.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.25 (dd, J = 8.1, 1.5 Hz, 1H), 7.20 – 7.11 (m, 2H), 7.10 – 7.01 (m, 
1H), 2.53 – 2.41 (m, 1H), 2.35 (s, 3H), 1.99 – 1.85 (m, 1H), 1.74 – 1.62 (m, 1H), 1.24 (s, 6H), 1.22 (s, 
6H), 0.96 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 141.8, 136.0, 130.0, 127.7, 125.9, 124.9, 83.2, 25.3, 24.7, 24.6, 20.2, 
14.1. 
FT-IR (film): 2977, 1463, 1371, 1322, 1144, 968, 850, 729 cm–1. 
GC-MS (EI) m/z (M)+ calcd for C16H25BO2: 260.2, found: 260.1. 
[α]23D = +14 (c = 1.0, CHCl3); 86% ee, from (R,S)-L1. 
 
 
 
2-(1-(2-Fluorophenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, Entry 14). 
The title compound was synthesized according to GP-2 from 1-(1-chloropropyl)-2-
fluorobenzene and B2pin2, and it was purified by column chromatography on silica gel (5% 
Et2O in hexanes). Colorless oil. 
(R,S)-L1: 159 mg, 86% yield, 82% ee; (S,R)-L1: 155 mg, 84% yield, 80% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL OD-H 
column (3% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 7.7 min (minor), 8.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.28 – 7.23 (m, 1H), 7.17 – 7.11 (m, 1H), 7.09 – 7.04 (m, 1H), 
7.04 – 6.97 (m, 1H), 2.46 (t, J = 7.7 Hz, 1H), 1.95 – 1.86 (m, 1H), 1.73 – 1.62 (m, 1H), 1.26 (s, 6H), 
1.25 (s, 6H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 161.0 (d, J = 242 Hz), 130.5 (d, J = 3 Hz), 130.4 (d, J = 4 Hz), 
126.7 (d, J = 8 Hz), 123.8 (d, J = 3 Hz), 115.0 (d, J = 33 Hz), 83.4, 24.7, 24.6, 24.5, 13.7. 
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FT-IR (film): 2978, 1490, 1362, 1325, 1144, 969, 851, 755 cm–1. 
GC-MS (EI) m/z (M)+ calcd for C15H22BFO2: 264.2, found: 264.1. 
[α]23D = +17 (c = 1.0, CHCl3); 82% ee, from (R,S)-L1. 
 
 
 
4,4,5,5-Tetramethyl-2-(1-(naphthalen-1-yl)propyl)-1,3,2-dioxaborolane (Table 2, Entry 15). 
The title compound was synthesized according to GP-2 from 1-(1-chloropropyl)naphthalene 
and B2pin2, and it was purified by column chromatography on silica gel (5% Et2O in hexanes). 
Colorless oil. 
(R,S)-L1: 189 mg, 91% yield, 84% ee; (S,R)-L1: 185 mg, 89% yield, 83% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL AD-H 
column (5% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 11.7 min (major), 12.9 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.26 – 8.17 (m, 1H), 7.87 (dd, J = 8.0, 1.6 Hz, 1H), 7.71 (ddd, J = 
6.2, 3.3, 0.8 Hz, 1H), 7.56 – 7.47 (m, 2H), 7.47 – 7.39 (m, 2H), 3.09 – 2.93 (m, 1H), 2.18 – 2.04 (m, 
1H), 1.97 – 1.84 (m, 1H), 1.26 (s, 6H), 1.22 (s, 6H), 1.04 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 139.9, 134.0, 132.3, 128.7, 125.8, 125.7, 125.3, 125.24, 125.20, 
124.2, 83.4, 25.3, 24.8, 24.6, 14.3. 
FT-IR (film): 2977, 1462, 1379, 1320, 1264, 1143, 967, 778 cm–1. 
GC-MS (EI) m/z (M)+ calcd for C19H25BO2: 296.2, found: 296.1. 
[α]23D = +39 (c = 1.0, CHCl3); 84% ee, from (R,S)-L1. 
 
 
 
2-(1-(Dibenzo[b,d]furan-4-yl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, 
Entry 16). The title compound was synthesized according to GP-2 from 4-(1-
chloropropyl)dibenzo[b,d]furan and B2pin2, and it was purified by column chromatography on 
silica gel (5% Et2O in hexanes). Colorless oil. 
(R,S)-L1: 205 mg, 87% yield, 51% ee; (S,R)-L1: 198 mg, 84% yield, 51% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL OD-H 
column (10% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 8.1 min (minor), 10.9 min (major). 
 S–14 
1H NMR (400 MHz, CDCl3) δ 7.97 (ddd, J = 7.6, 1.4, 0.7 Hz, 1H), 7.79 (dd, J = 7.5, 1.4 Hz, 1H), 
7.59 (dt, J = 8.3, 1.0 Hz, 1H), 7.46 (ddd, J = 8.3, 7.3, 1.3 Hz, 1H), 7.41 – 7.33 (m, 2H), 7.33 – 7.27 (m, 
1H), 2.84 (t, J = 7.8 Hz, 1H), 2.15 – 2.00 (m, 1H), 1.99 – 1.83 (m, 1H), 1.29 (s, 6H), 1.25 (s, 6H), 1.00 
(t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.9, 154.8, 127.7, 127.2, 126.7, 124.9, 123.6, 122.8, 122.4, 120.6, 
117.6, 111.6, 83.4, 24.7, 24.6, 24.5, 14.0. 
FT-IR (film): 2976, 2870, 1451, 1378, 1187, 1143, 968, 846, 752 cm–1. 
GC-MS (EI) m/z (M+H)+ calcd for C21H26BO3: 337.2, found: 337.2. 
[α]24D = +25 (c = 1.0, CHCl3); 51% ee, from (R,S)-L1. 
 
 
 
4,4,5,5-Tetramethyl-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3,2-dioxaborolane (Table 2, 
Entry 17). The title compound was synthesized according to GP-2 from 1-chloro-1,2,3,4-
tetrahydronaphthalene and B2pin2, and it was purified by column chromatography on silica 
gel (5% Et2O in hexanes). Colorless oil. 
(R,S)-L1: 143 mg, 79% yield, 81% ee; (S,R)-L1: 150 mg, 83% yield, 81% ee. 
HPLC analysis: After oxidation (GP-3), the ee was determined on a CHIRALCEL AD-H 
column (5% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(R,S)-L1: 9.1 min (major), 9.9 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.18 – 7.13 (m, 1H), 7.12 – 7.03 (m, 3H), 2.80 (td, J = 6.0, 2.5 Hz, 
2H), 2.62 (t, J = 6.4 Hz, 1H), 1.99 – 1.87 (m, 3H), 1.84 – 1.72 (m, 1H), 1.28 (s, 6H), 1.27 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 137.6, 136.6, 129.4, 129.3, 125.3, 124.8, 83.3, 29.8, 25.1, 24.7, 24.6, 
22.7. 
FT-IR (film): 2977, 1449, 1379, 1327, 1144, 970, 854, 737 cm–1. 
LC-MS (ESI) m/z (M+H)+ calcd for C16H24BO2: 259.2, found: 259.2. 
[α]23D = +10 (c = 1.0, CHCl3); 81% ee, from (R,S)-L1. 
 
  
 S–15 
IV. Effect of Reaction Parameters 
 
General Procedure 4 (GP-4): Effect of reaction parameters. This procedure was carried out 
in a nitrogen-filled glove box. 
Preparation of the catalyst. An oven-dried 4 mL vial that contained a magnetic stir bar was 
charged with NiCl2·glyme (4.4 mg, 0.020 mmol, 10 mol%), L1 (9.4 mg, 0.024 mmol, 12 mol%), 
and DME (1.0 mL). The vial was capped with a PTFE-lined septum cap, and the reaction 
mixture was stirred at room temperature for 1 h. 
Preparation of a solution of the nucleophile. An oven-dried 4 mL vial that contained a 
magnetic stir bar was charged in turn with t-BuOK (31 mg, 0.28 mmol, 1.4 equiv), CPME (0.60 
mL), and 2-phenylethanol (36 µL, 0.30 mmol, 1.5 equiv). The resulting suspension was stirred 
at room temperature for 3 min, and then B2pin2 (71 mg, 0.28 mmol, 1.4 equiv) was added. The 
vial was then capped, and the resulting suspension was stirred at room temperature for 40 
min. 
Enantioconvergent borylation. The benzylic chloride (0.20 mmol, 1.0 equiv) was added via 
syringe to the suspension of the catalyst. The resulting mixture was stirred for 5 min, and then 
the solution of the nucleophile was added via syringe over ~1 min. Then, the vial was capped 
and removed from the glove box. The reaction mixture was stirred at room temperature for 3 
h. 
Workup. n-Dodecane (46 µL, 0.20 mmol) was added to the reaction mixture via syringe. 
Then, the reaction mixture was filtered through a short pad of silica gel, eluting with Et2O (5.0 
mL). The yield was determined via GC analysis. 
Determination of enantioselectivity. The filtered reaction mixture was concentrated, and 
then the residue was dissolved in THF/H2O (1:1; 4.0 mL). Next, NaBO3·4H2O (~150 mg) was 
added, and the resulting mixture was stirred vigorously at room temperature for 4 h. Then, the 
mixture was extracted with Et2O (4.0 mL). The resulting organic phase was dried over 
anhydrous Na2SO4 and concentrated, and the residue was purified by preparative thin-layer 
chromatography. The ee of the benzylic alcohol was determined via HPLC analysis. 
 
(1-Chloropropyl)benzene was reacted with B2pin2 according to GP-4. The yields were 
determined via GC analysis, using n-dodecane as an internal standard. The ee’s were 
determined via HPLC analysis, after stereospecific oxidation of the reaction mixture and 
purification by preparative thin-layer chromatography. All data are the average of two 
experiments. A negative value for ee signifies that the major product is the R enantiomer. 
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V. Effect of Additives 
 
(1-Chloropropyl)benzene was reacted with B2pin2 according to GP-4, in the presence of 1.0 
equiv of each of the additives shown below. The additive was added after the addition of (1-
chloropropyl)benzene. 
The yields were determined via GC analysis, using n-dodecane as an internal standard. The 
ee’s were determined via HPLC analysis, after stereospecific oxidation of the reaction mixture 
and purification by preparative thin-layer chromatography. All data are the average of two 
experiments. 
 
Table S–1. 
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VI. Derivatization of the Borylation Products 
 
 
tert-Butyl (1-phenylpentyl)carbamate (Figure 3).4 An oven-dried 25 mL flask equipped 
with a magnetic stir bar and a septum was evacuated and backfilled with N2 (3 cycles). A 
solution of O-methylhydroxylamine (2.8 M in THF; 0.43 mL, 1.2 mmol, 3.0 equiv) was added, 
followed by anhydrous THF (4.0 mL). The reaction flask was cooled to –78 °C in a dry-
ice/acetone bath. A solution of n-BuLi (2.4 M in hexanes; 0.50 mL, 1.2 mmol, 3.0 equiv) was 
added dropwise via syringe over 1 min, and then the reaction mixture was stirred at –78 °C for 
30 min. Next, a solution of 4,4,5,5-tetramethyl-2-(1-phenylpentyl)-1,3,2-dioxaborolane (110 mg, 
0.40 mmol, 1.0 equiv) in anhydrous THF (1.0 mL) was added dropwise via syringe over 1 min 
to the solution of deprotonated O-methylhydroxylamine. The reaction flask was allowed to 
warm to room temperature, and then it was heated to 60 °C. After stirring at 60 °C for 12 h, the 
flask was allowed to cool to room temperature, and then Boc2O (0.29 mL, 1.3 mmol, 3.2 equiv) 
was added. After stirring at room temperature for 1 h, the reaction was quenched by the 
addition of water (8.0 mL). The layers were separated, and the aqueous layer was extracted 
with EtOAc (3 x 20 mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered, and concentrated. The residue was purified by column chromatography (5%→10% 
EtOAc in hexanes) to provide the desired product as a white solid. 
(R,S)-L1: 81 mg, 77% yield, 88% ee; (S,R)-L1: 88 mg, 84% yield, 88% ee. 
HPLC analysis: The ee was determined on a CHIRALPAK IC column (3% i-PrOH in 
hexane, 1.0 mL/min); retention times for compound obtained using (R,S)-L1: 6.0 min (minor), 
7.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.29 – 7.22 (m, 2H), 7.20 – 7.15 (m, 3H), 4.97 – 4.59 (m, 1H), 
4.59 – 4.20 (m, 1H), 1.81 – 1.58 (m, 2H), 1.34 (s, 9H), 1.26 – 1.15 (m, 4H), 0.80 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.2, 143.2, 128.5, 127.0, 126.3, 79.3, 54.9, 36.8, 28.4, 28.3, 22.5, 
14.0. 
FT-IR (film): 3379, 2957, 1683, 1521, 1253, 1174, 1010, 703 cm–1. 
LC-MS (ESI) m/z (M+Na)+ calcd for C16H25NO2Na: 286.2, found: 286.2. 
[α]23D = –28 (c = 1.0, CHCl3); 88% ee, from (R,S)-L1. 
 
 
  
                                                
[4] S. N. Mlynarski, A. S. Karns, J. P. Morken, J. Am. Chem. Soc. 2012, 134, 16449–16451. 
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2-Phenylhexan-1-ol (Figure 3).5 An oven-dried 25 mL flask equipped with a magnetic stir 
bar and a septum, was evacuated and backfilled with N2 (3 cycles), and then 4,4,5,5-
tetramethyl-2-(1-phenylpentyl)-1,3,2-dioxaborolane (110 mg, 0.40 mmol, 1.0 equiv), 
bromochloromethane (52 µL, 0.80 mmol, 2.0 equiv), and anhydrous Et2O (8.0 mL) were added 
via syringe sequentially. The reaction flask was cooled to –78 °C in a dry-ice/acetone bath. 
Then, a solution of n-BuLi in hexanes (2.4 M; 0.32 mL, 0.80 mmol, 2.0 equiv) was added 
dropwise via syringe over 1 min. The reaction mixture was allowed to slowly warm to room 
temperature and then stirred for 2 h. Next, the reaction was quenched by the addition of a 
saturated aqueous solution of NH4Cl (5.0 mL), and the mixture was extracted with Et2O (3 x 10 
mL), dried over anhydrous MgSO4, filtered, and concentrated. The residue was then dissolved 
in Et2O (6.0 mL). MeOH (1.0 mL), aqueous NaOH (2 N; 2.0 mL), and then aqueous H2O2 (30 
weight% in H2O; 0.20 mL) were added. The reaction mixture was then allowed to warm to 
room temperature and stirred overnight. Next, the layers were separated, and the aqueous 
layer was extracted with Et2O (3 x 15 mL). The combined organic layers were dried over 
anhydrous MgSO4, filtered, and concentrated. The residue was purified by column 
chromatography (10% EtOAc in hexanes), which furnished the desired product as a colorless 
oil. 
(R,S)-L1: 61 mg, 86% yield, 88% ee; (S,R)-L1: 63 mg, 88% yield, 88% ee. 
HPLC analysis: The ee was determined on a CHIRALCEL AD-H column (1% i-PrOH in 
hexane, 1.0 mL/min); retention times for compound obtained using (R,S)-L1: 10.4 min (minor), 
11.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.29 – 7.22 (m, 2H), 7.18 – 7.12 (m, 3H), 3.71 – 3.58 (m, 2H), 
2.78 – 2.60 (m, 1H), 1.68 – 1.57 (m, 1H), 1.55 – 1.44 (m, 1H), 1.25 – 1.16 (m, 2H), 1.15 – 1.02 (m, 
2H), 0.77 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 142.5, 128.6, 128.1, 126.7, 67.7, 48.7, 31.8, 29.6, 22.8, 14.0. 
FT-IR (film): 3349, 2929, 1494, 1453, 1054, 1017, 758, 699 cm–1. 
GC-MS (EI) m/z (M)+ calcd for C12H18O: 178.1, found: 178.1. 
[α]23D = +14 (c = 1.0, CHCl3); 88% ee, from (R,S)-L1. 
 
 
  
                                                
[5] A. Chen, L. Ren, C. M. Crudden, J. Org. Chem. 1999, 64, 9704–9710. 
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3-Fluoro-4-(1-phenylpentyl)pyridine (Figure 3).6 An oven-dried 25 mL flask equipped 
with a magnetic stir bar and a septum was evacuated and backfilled with N2 (3 cycles). 
Diisopropylamine (112 µL, 0.80 mmol, 2.0 equiv) and anhydrous THF (2.0 mL) were added 
sequentially. The reaction flask was cooled to –60 °C. A solution of n-BuLi in hexanes (2.4 M; 
0.37 mL, 0.88 mmol, 2.2 equiv) was added dropwise via syringe over 1 min, and the resulting 
mixture was stirred at –60 °C for 30 min. Then, a solution of 3-fluoropyridine (69 µL, 0.80 
mmol, 2.0 equiv) in anhydrous THF (1.0 mL) was added dropwise via syringe over 1 min, and 
the resulting mixture was stirred at –60 °C for 30 min. Next, the mixture was cooled to –78 °C, 
and a solution of 4,4,5,5-tetramethyl-2-(1-phenylpentyl)-1,3,2-dioxaborolane (110 mg, 0.40 
mmol, 1.0 equiv) in anhydrous THF (1.0 mL) was added dropwise via syringe over 1 min. The 
reaction mixture was stirred at –78 °C for 2 h, and then 2,2,2-trichlorethoxycarbonyl chloride 
(220 µL, 1.6 mmol, 4.0 equiv) was added. The resulting mixture was stirred at –78 °C for 8 h 
and then allowed to warm to room temperature overnight. Next, the mixture was diluted with 
Et2O (10 mL) and H2O (5.0 mL), the layers were separated, and the aqueous layer was 
neutralized with saturated aqueous NaHCO3 (5.0 mL). The aqueous layer was extracted with 
Et2O (2 x 10 mL). The combined organic layers were dried over anhydrous MgSO4, filtered, 
and concentrated. The residue was dissolved in THF (2.0 mL) and cooled to 0 °C. Aqueous 
NaOH (2 M; 1.6 mL) and aqueous H2O2 (30 weight% in H2O; 1.6 mL) were added sequentially, 
and the mixture was stirred at room temperature for 12 h. Et2O (10 mL) was then added, and 
the layers were separated. The aqueous layer was acidified with aqueous HCl (1 M; 5.0 mL) 
and extracted with Et2O (2 x 10 mL). The aqueous layer was then neutralized with saturated 
aqueous NaHCO3 (10 mL) and extracted with Et2O (2 x 10 mL). The combined organic layers 
were dried over anhydrous MgSO4, filtered, and concentrated. The residue was purified by 
column chromatography (10%→20% EtOAc in hexanes), which provided the desired product 
as a pale-yellow oil. 
(R,S)-L1: 68 mg, 70% yield, 88% ee; (S,R)-L1: 72 mg, 74% yield, 88% ee. 
HPLC analysis: The ee was determined on a CHIRALCEL OD-H column (10% i-PrOH in 
hexane, 1.0 mL/min); retention times for compound obtained using (R,S)-L1: 5.6 min (major), 
6.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 1.9 Hz, 1H), 8.25 (dd, J = 5.0, 0.9 Hz, 1H), 7.26 – 7.21 
(m, 2H), 7.19 – 7.12 (m, 4H), 4.18 (t, J = 7.8 Hz, 1H), 2.03 – 1.92 (m, 2H), 1.31 – 1.24 (m, 2H), 1.22 
– 1.15 (m, 2H), 0.80 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.9 (d, J = 252 Hz), 145.8 (d, J = 5 Hz), 142.1, 140.8 (d, J = 12 
Hz), 138.0 (d, J = 25 Hz), 128.7, 127.9, 126.8, 122.9 (d, J = 2 Hz), 43.1 (d, J = 1 Hz), 33.9, 29.9, 22.5, 
13.9. 
                                                
[6] J. Llaveria, D. Leonori, V. K. Aggarwal, J. Am. Chem. Soc. 2015, 137, 10958–10961. 
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FT-IR (film): 3029, 2931, 1600, 1491, 1413, 1243, 839, 699 cm–1. 
GC-MS (EI) m/z (M)+ calcd for C16H18FN: 243.1, found: 243.1. 
[α]23D = –3.9 (c = 1.0, CHCl3); 88% ee, from (R,S)-L1. 
 
 
 
2-(1-Phenylpentyl)thiophene (Figure 3).7 An oven-dried 25 mL flask equipped with a 
magnetic stir bar and a septum was evacuated and backfilled with N2 (3 cycles), and then 
thiophene (45 µL, 0.56 mmol, 1.4 equiv) and anhydrous THF (2.0 mL) were added 
sequentially. The reaction flask was cooled to –78 °C in a dry-ice/acetone bath, and then a 
solution of n-BuLi in hexanes (2.4 M; 0.23 mL, 0.56 mmol, 1.4 equiv) was added dropwise by 
syringe over 1 min. Next, the reaction mixture was allowed to warm to 0 °C and stirred for 30 
min. The mixture was then cooled to –78 °C, and a solution of 4,4,5,5-tetramethyl-2-(1-
phenylpentyl)-1,3,2-dioxaborolane (110 mg, 0.40 mmol, 1.0 equiv) in anhydrous THF (1.0 mL) 
was added dropwise via syringe over 1 min. The resulting mixture was stirred at –78 °C for 1 
h, and then a solution of N-bromosuccinimide (100 mg, 0.56 mmol, 1.4 equiv) in anhydrous 
THF (1.0 mL) was added dropwise. After 1 h at –78 °C, saturated aqueous Na2SO3 (2.0 mL) was 
added, and the reaction mixture was allowed to warm to room temperature. The reaction 
mixture was diluted with EtOAc (10 mL) and water (5.0 mL). The layers were separated, and 
the aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic layers were 
dried over anhydrous MgSO4, filtered, and concentrated. The residue was purified by column 
chromatography (15% CH2Cl2 in hexanes), which provided the desired product as a colorless 
oil. 
(R,S)-L1: 78 mg, 85% yield, 88% ee; (S,R)-L1: 75 mg, 81% yield, 88% ee. 
HPLC analysis: The ee was determined on a CHIRALCEL OJ-H column (5% i-PrOH in 
hexane, 1.0 mL/min); retention times for compound obtained using (R,S)-L1: 10.6 min (minor), 
12.4 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.29 (m, 4H), 7.28 – 7.21 (m, 1H), 7.17 (dd, J = 5.1, 1.2 Hz, 
1H), 6.95 (dd, J = 5.1, 3.5 Hz, 1H), 6.85 (dt, J = 3.5, 1.1 Hz, 1H), 4.24 – 4.04 (m, 1H), 2.23 – 1.98 (m, 
2H), 1.45 – 1.24 (m, 4H), 0.91 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 149.9, 144.8, 128.5, 127.7, 126.50, 126.46, 123.6, 123.3, 46.9, 37.2, 
30.1, 22.6, 14.0. 
FT-IR (film): 3027, 2929, 1494, 1453, 696 cm–1. 
GC-MS (EI) m/z (M)+ calcd for C15H18S: 230.1, found: 230.0. 
[α]23D = +19 (c = 1.0, CHCl3); 88% ee, from (R,S)-L1.  
                                                
[7] A. Bonet, M. Odachowski, D. Leonori, S. Essafi, V. K. Aggarwal, Nat. Chem. 2014, 6, 584–
589. 
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VII. Mechanistic Study 
 
Enantioenriched (1-chloroethyl)benzene was obtained via HPLC resolution on a chiral OB-
H column (pentane, 2.5 mL/min); retention times: 5.9 min ((S)-(1-chloroethyl)benzene, 94% ee), 
6.7 min ((R)-(1-chloroethyl)benzene, 90% ee). 
 
 
Enantioenriched (1-chloroethyl)benzene was reacted with B2pin2 according to GP-4. The 
conversion and the yield were determined via GC analysis, using n-dodecane as an internal 
standard. The ee of the product was determined via HPLC analysis, after stereospecific 
oxidation of the reaction mixture and purification by preparative thin-layer chromatography. 
The ee of (1-chloroethyl)benzene was determined via GC analysis. 
 
 
(R)-(1-Chloroethyl)benzene. The ee was determined via GC analysis on a CHIRALDEX G-
TA column (80 – 180 °C, ramp: 5 °C /min); retention times: 6.2 min (major), 6.4 (minor). 
 
 
(S)-(1-Chloroethyl)benzene. The ee was determined via GC analysis on a CHIRALDEX G-
TA column (80 – 180 °C, ramp: 5 °C /min); retention times: 6.2 min (minor), 6.4 (major). 
 
  
Ph Me
Cl
B2pin2
1.4 equiv
Ph Me
Bpinsee eq 1
90% ee 49% yield, 82% ee
at 68% conversion (5 min): 
    unreacted electrophile: 90% ee
(2)
Ph Me
Cl
B2pin2
1.4 equiv
Ph Me
Bpin
94% ee 50% yield, 81% ee
at 71% conversion (5 min): 
    unreacted electrophile: 94% ee
(3)
see eq 1
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VIII. Assignment of Absolute Configuration 
 
(S)-1-Phenylethan-1-ol. 4,4,5,5-Tetramethyl-2-(1-phenylethyl)-1,3,2-dioxaborolane was 
prepared according GP-2, using (R,S)-L1. The boronate ester was stereospecifically oxidized as 
described in GP-3 to give (S)-1-phenylethan-1-ol. 
HPLC analysis: The ee was determined on a CHIRALCEL OD-H column (3% i-PrOH in 
hexanes, 1.0 mL/min): retention times: 11.7 min (minor), 14.8 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.34 (m, 4H), 7.33 – 7.26 (m, 1H), 4.91 (qd, J = 6.5, 2.6 Hz, 
1H), 2.14 (s, 1H), 1.52 (d, J = 6.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 145.8, 128.5, 127.5, 125.4, 70.4, 25.2. 
Determination of the absolute configuration: The absolute configuration was assigned by 
comparing the retention time to commercially available 1-phenylethan-1-ol, under the same 
conditions: (R)-1-phenylethan-1-ol [1517-69-7] 11.2 min (major); (S)-1-phenylethan-1-ol [1445-
91-6] 14.4 min (major). 
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S-72
ee Analysis 
 
 
4,4,5,5-Tetramethyl-2-(1-phenylpropyl)-1,3,2-dioxaborolane (Table 2, entry 1). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL OD-H column (3% i-PrOH in hexane, 1.0 mL/min). 
86% ee from (R,S)-L1 
 
 
86% ee from (S,R)-L1 
 
 
  
S-73
 4,4,5,5-Tetramethyl-2-(1-phenylethyl)-1,3,2-dioxaborolane (Table 2, entry 2). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL OD-H column (3% i-PrOH in hexane, 1.0 mL/min). 
82% ee from (R,S)-L1 
 
 
81% ee from (S,R)-L1 
 
 
 
  
S-74
 4,4,5,5-Tetramethyl-2-(1-phenylpentyl)-1,3,2-dioxaborolane (Table 2, entry 3). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL OD-H column (3% i-PrOH in hexane, 1.0 mL/min). 
88% ee from (R,S)-L1 
 
 
87% ee from (S,R)-L1 
 
 
  
S-75
 4,4,5,5-Tetramethyl-2-(3-methyl-1-phenylbutyl)-1,3,2-dioxaborolane (Table 2, entry 4). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL OD-H column (3% i-PrOH in hexane, 1.0 mL/min). 
88% ee from (R,S)-L1 
 
 
87% ee from (S,R)-L1 
 
 
  
S-76
 2-(Cyclohexyl(phenyl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, entry 5). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL OD-H column (3% i-PrOH in hexane, 1.0 mL/min). 
78% ee from (R,S)-L1 
 
 
77% ee from (S,R)-L1 
 
 
 
  
S-77
 2-(1,2-Diphenylethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, entry 6). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL OD-H column (5% i-PrOH in hexane, 1.0 mL/min). 
82% ee from (R,S)-L1 
 
 
84% ee from (S,R)-L1 
 
 
 
  
S-78
 2-(6-(Benzyloxy)-1-phenylhexyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, entry 7). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL AD-H column (3% i-PrOH in hexane, 1.0 mL/min). 
80% ee from (R,S)-L1 
 
 
79% ee from (S,R)-L1 
 
 
 
  
S-79
 6-Phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexyl benzoate (Table 2, entry 8). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL AD-H column (10% i-PrOH in hexane, 1.0 mL/min). 
84% ee from (R,S)-L1 
 
 
82% ee from (S,R)-L1 
 
 
 
 
  
S-80
 2-(6-Chloro-1-phenylhexyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, entry 9). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALPAK IC column (3% i-PrOH in hexane, 1.0 mL/min). 
86% ee from (R,S)-L1 
 
 
87% ee from (S,R)-L1 
 
 
  
S-81
 4,4,5,5-Tetramethyl-2-(1-(p-tolyl)propyl)-1,3,2-dioxaborolane (Table 2, entry 10). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL AD-H column (5% i-PrOH in hexane, 1.0 mL/min). 
82% ee from (R,S)-L1 
 
 
82% ee from (S,R)-L1 
 
 
 
  
S-82
 4,4,5,5-Tetramethyl-2-(1-(m-tolyl)propyl)-1,3,2-dioxaborolane (Table 2, entry 11). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL OD-H column (5% i-PrOH in hexane, 1.0 mL/min). 
81% ee from (R,S)-L1 
 
 
82% ee from (S,R)-L1 
 
 
  
S-83
 2-(1-(3-Methoxyphenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, entry 12). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL OD-H column (3% i-PrOH in hexane, 1.0 mL/min). 
82% ee from (R,S)-L1 
 
 
80% ee from (S,R)-L1 
 
 
 
  
S-84
 4,4,5,5-Tetramethyl-2-(1-(o-tolyl)propyl)-1,3,2-dioxaborolane (Table 2, entry 13). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL AD-H column (3% i-PrOH in hexane, 1.0 mL/min). 
86% ee from (R,S)-L1 
 
 
86% ee from (S,R)-L1 
 
 
  
S-85
 2-(1-(2-Fluorophenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, entry 14). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL OD-H column (3% i-PrOH in hexane, 1.0 mL/min). 
82% ee from (R,S)-L1 
 
 
80% ee from (S,R)-L1 
 
 
S-86
 4,4,5,5-Tetramethyl-2-(1-(naphthalen-1-yl)propyl)-1,3,2-dioxaborolane (Table 2, entry 15). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL AD-H column (5% i-PrOH in hexane, 1.0 mL/min). 
84% ee from (R,S)-L1 
 
 
83% ee from (S,R)-L1 
 
 
  
S-87
 2-(1-(Dibenzo[b,d]furan-4-yl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, entry 16). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL OD-H column (10% i-PrOH in hexane, 1.0 mL/min). 
51% ee from (R,S)-L1 
 
 
51% ee from (S,R)-L1 
 
 
  
S-88
 4,4,5,5-Tetramethyl-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3,2-dioxaborolane (Table 2, entry 17). 
Determination of the ee: stereospecific oxidation according to GP-3. 
 
HPLC analysis: CHIRALCEL AD-H column (5% i-PrOH in hexane, 1.0 mL/min). 
81% ee from (R,S)-L1 
 
 
81% ee from (S,R)-L1 
 
 
 
  
S-89
 tert-Butyl (1-phenylpentyl)carbamate (Fig. 3). 
HPLC analysis: CHIRALPAK IC column (3% i-PrOH in hexane, 1.0 mL/min). 
88% ee from (R,S)-L1 
 
 
88% ee from (S,R)-L1 
 
 
 
  
S-90
 2-Phenylhexan-1-ol (Fig. 3). 
HPLC analysis: CHIRALCEL AD-H column (1% i-PrOH in hexane, 1.0 mL/min). 
88% ee from (R,S)-L1 
 
 
88% ee from (S,R)-L1 
 
 
 
  
S-91
 3-Fluoro-4-(1-phenylpentyl)pyridine (Fig. 3). 
HPLC analysis: CHIRALCEL OD-H column (10% i-PrOH in hexane, 1.0 mL/min). 
88% ee from (R,S)-L1 
 
 
88% ee from (S,R)-L1 
 
 
 
  
S-92
 2-(1-Phenylpentyl)thiophene (Fig. 3). 
HPLC analysis: CHIRALCEL OJ-H column (5% i-PrOH in hexane, 1.0 mL/min). 
88% ee from (R,S)-L1 
 
 
88% ee from (S,R)-L1 
 
 
 
  
S-93
 (1-Chloroethyl)benzene (eq 2 and 3). 
GC analysis: CHIRALDEX G-TA column (80 – 180 °C, ramp: 5 °C /min). 
(R)-(1-chloroethyl)benzene: 90% ee 
 
 
(S)-(1-chloroethyl)benzene: 94% ee 
 
 
S-94
